In some studies, c-Met staining with moderate (2+) or strong (3+) intensity in ≥50% of tumor cells was used.3,63 Thus far, c-Met overexpression by IHC has not been determined to be an effective clinical biomarker with a clear cutoff. This evidence concerns the gene MET and neoplasm.